BYD, the Chinese electric-vehicle maker, has filed a lawsuit against the U.S. government challenging the use of the International Emergency Economic Powers Act (IEEPA) to impose tariffs and seeking a refund for all levies paid since last April. The suit, filed at the U.S. Court of International Trade on January 26, alleges the statute does not authorize border taxes as its text does not employ the word "tariff" or equivalent terms.

BYD North America, which employs 750 workers in Lancaster, California, and operates in North America in commercial vehicles, batteries, energy storage and solar, is among the entities involved. The U.S. Supreme Court is expected to rule on the legality of the tariffs, with officials noting the high stakes involved. The case is No. 26-00847.

Alphabet Inc. (GOOGL) is seeking to raise about $15 billion in a US high-grade bond offering, continuing its aggressive borrowing to support expanding AI infrastructure.

Hyperscalers are forecast to invest over $650 billion this year in AI, with Alphabet planning up to $185 billion in spending this year. The company is expected to sell bonds in as many as seven tranches, with initial discussions for the 2066 maturity at a premium of about 1.2 percentage points above Treasuries. The offering is likely to be supported by a rare 100-year Swiss franc or sterling note.

The company last accessed the US bond market in November 2025 with a $17.5 billion offering that attracted about $90 billion in orders. Bloomberg Intelligence estimates global AI, cloud and data center capital spending will reach $3 trillion by 2029.

Alphabet Inc. (GOOGL) is reportedly seeking to raise about $15 billion in a U.S. high-grade dollar bond offering, according to Bloomberg News, citing sources familiar with the matter. The potential issuance would be the largest corporate bond sale in U.S. history, with proceeds likely used to refinance existing debt and support strategic growth. The report reflects ongoing discussions within the company regarding its capital structure and liquidity needs ahead of its upcoming earnings report on February 13, 2026.

Morgan Stanley strategists note that despite recent volatility, U.S. technology stocks remain attractive as AI-driven demand and enterprise sales outlooks support earnings and growth. The bank argues that large tech companies now trade at multi-decade high earnings growth expectations, while software stocks' recent corrections present opportunities for Microsoft (MSFT-US) and Intuit (INTU-US).

Michael Wilson's team highlights that AI's supply-side fundamentals remain intact, and the market has yet to fully price the growth from AI application spending. The "Magnificent Seven" index trades at about 29x earnings, slightly below the five-year average, with some逢低 buying evident but Nasdaq 100 futures down 0.7% on Monday.

They emphasize CAPEX-relative-to-sales stocks continue outperforming, and companies integrating AI into core operations outperform broad-market peers by roughly 1% in the next trading day. Weaker dollars also benefit the sector, as roughly half of the Nasdaq 100's revenue is international, with broader upside in semiconductors, software, and hardware expected.

The New York Stock Exchange is expected to open with cautious trading on February 09, 2026, as investors digest mixed economic data and evolving Fed policy signals. The Dow Jones Industrial Average, S&P 500, and Nasdaq 100 are projected to trade flat to slightly lower in the early session, with a focus on earnings season and potential rate cuts in the coming months.

Key indicators include the Federal Reserve's latest statement indicating a pause in加息 decisions, while the January nonfarm payrolls rose by 200,000, and the unemployment rate held steady at 3.8%. The market remains closely watched for the upcoming jobs report and inflation data, which will influence the timing and幅度 of any policy moves.

NervGen Pharmaceuticals (NVRV) announced on February 9, 2026, the appointment of Adam Rogers as its new Chief Executive Officer, effective March 1, 2026. The move follows the departure of the previous CEO, who stepped down to focus on a new venture. Rogers, currently President and COO, will lead the biopharmaceutical company as it advances its pipeline of therapies for rare neurological disorders. The company reported revenue of $12.5 million in 2024, with a strong focus on Phase III trials for its lead candidate, NVP-007.

MannKind (MNK.US) announced it has initiated the first pediatric trial of Afrezza inhalation insulin in patients with newly diagnosed Type 1 diabetes. The single-blind, placebo-controlled study will enroll 60 patients aged 6-18 across the U.S., with results expected by the end of 2026. The trial evaluates safety, tolerability, and glucose control, aiming to support potential regulatory approval by 2027. Afrezza, launched in 2016, is approved for adults with Type 2 diabetes.

Universal Corp (UNVR) released Q3 2025 results, reporting revenue of $1.8B, a 7.2% year-over-year decline. Net income fell to $165 million, or $0.12 per share, versus $210 million, or $0.16 per share, in the same period of 2024. The decline followed soft demand in North America and continued pressure on pricing from increased competition. The company attributed the results to supply chain disruptions and higher input costs, with guidance for Q4 revenue of $1.95B, reflecting cautious outlook.

As of February 6, 2026, 59% of S&P 500 (^GSPC) companies have released fourth-quarter earnings, according to FactSet. Analysts estimate a 13% increase in earnings per share for Q4, on pace for the 10th consecutive quarter of annual earnings growth and the fifth consecutive quarter of double-digit gains. Expectations for Q4 EPS growth stand at 8.3%, down from 13.6% in the prior quarter, reflecting higher guidance especially in technology sectors. Key themes — AI investment, policy-driven macroeconomic dynamics, and a K-shaped consumer economy — continue to shape earnings expectations this week. Major reportees include KO, SPOT, HOOD, LYFT, F, RIVN, MRNA, ABNB, and COIN.

Kyndryl has delayed the filing of its quarterly report, citing anticipated material weaknesses in internal control over financial reporting for fiscal 2026 Q1 and Q2. The company warned it may miss the filing deadline following a review of cash management practices, related disclosures and internal controls initiated after the SEC enforcement division requested voluntary documents.

Premarket trading on the company’s stock (NASDAQ: KYND) fell 38% as the news emerged. The board has also removed David Wyshner as finance chief and Vineet Khurana as global controller, effective immediately, and appointed Harsh Chugh as interim CFO and Bhavna Doegar as interim corporate controller.

Kyndryl (KYND) downgraded its full-year revenue guidance to a 2%-3% constant-currency decline, missing Q3 estimates and reporting lower-than-expected profit. The downgrade follows a review of its financial reporting practices at the request of the SEC, with the company任命 of interim CFO Harsh Chugh, interim corporate controller Bhanva Doegar, and general counsel Mark Ringes.

The company now projects adjusted pretax income of $575M-$600M and free cash flow of $325M-$375M, down from prior guidance of at least $725M pretax and about $550M free cash. Q3 results: profit $57M (25¢/share) vs. $215M (89¢/share) a year earlier; non-GAAP 52¢/share vs. 60¢/share expected; revenue $3.86B, up from $3.74B and ahead of $3.89B expected. Cloud hyperscaler revenue reached $500M, up 58% YoY, on track to exceed $1.8B for the year; Kyndryl Consult revenue up 24% YoY.

The 10-Q will be delayed as the board reviews cash management, free cash flow disclosures and broader reporting. The company anticipates material weakness in internal control over financial reporting for Q3 and FY2025, with prior audits not deemed reliable. The review is not expected to result in restatements or impact financial statements.

AI integration in radiology demonstrates how automation can augment, rather than replace, human workers. The field, rich with digitized imaging data, uses AI to prioritize scans, enhance image quality, and assist in report summarization. Despite early warnings, such as a 2016 claim AI would soon outperform radiologists, current practice emphasizes a "second set of eyes" reviewed by experts.

Regulatory approval for medical AI can take about eight years, but over 1,357 AI-enabled devices are FDA-approved, with 1,041 designated for radiology. Despite concerns over bias and overreliance, the U.S. Bureau of Labor Statistics projects radiology employment to grow 5% from 2024 to 2034, outpacing the 3% average. Demand is driven by an aging population and expanded medical imaging use, not displacement.

Jerash Holdings (US), Inc. (JRSH) reported net income of $1.2 million for fiscal Q3 ended December 31, 2025, translating to $0.09 per share. Revenue for the quarter totaled $41.8 million, reflecting continued operational performance.

Bitcoin’s mining difficulty fell 11% to 125.86T, its largest drop since the 2021 crackdown, as hashrate plunged due to plunging prices and winter storm outages in the U.S. The adjustment interval maintains a 10-minute block time. Prices slid from $126,000 to $69,500, pushing many miners offline and repurposing rigs toward AI workloads. Bitfarms (BITF) shares rose as the firm shifted focus to AI/HPCC data centers. Hashprice, a per-terahash measure, fell from ~$70 to <$35. Severe curtailments in Texas reduced output by over 60% for some. While lower difficulty eases block validation, it may also indicate miner-driven capitulation, with remaining miners gaining efficiency and the broader market seeking stabilization.

PowerFleet, Inc. (PWR) released Q3 2025 earnings, reporting revenue of $248 million, a 12% increase from $221 million in the same period of 2024. Net income attributable to common shareholders was $32 million, or $0.29 per share, up from $25 million, or $0.23 per share, in Q3 2024. The company attributed the growth to higher fleet utilization and strong demand in North America. The report was issued on February 9, 2026 (02/09/2026).

Lilly (LLY) agreed to acquire Orna Therapeutics in a cash deal valued at up to $2.4 billion, subject to regulatory approvals and the achievement of certain development milestones. The acquisition targets Orna’s RNA-based therapeutics platform, including its lead candidate OR-2001, a potential treatment for rare genetic disorders. The transaction is expected to be completed by the end of 2026, pending closing conditions.

Microchip Technology (MCHP) announced on February 9, 2026, the issuance of $600 million in privately placed convertible senior notes. The offering is designed to strengthen its balance sheet and support ongoing R&D and growth initiatives. Terms include a coupon rate of 6.75% and a conversion price of $0.50 per share, with a maturity date of 2029. The proceeds will be used to fund strategic growth and operational needs, with placement to be made with a select group of institutional investors.

Hain Celestial (HCN) reported a wider second-quarter loss of $18.5 million, or 14.4 cents per share, compared to a $12.2 million loss in the same period last year, on February 9, 2026. The results reflect continued weakness in the natural-sugar and weight-management segments, with net sales down 12.3% year-over-year to $297.4 million. Management attributed the decline to shifting consumer preferences and supply chain disruptions, with no guidance provided for full-year 2026 revenue or earnings.

Cleveland-Cliffs (CLFS) will hold its Q4 2025 earnings conference call at 8:30 a.m. Eastern Time on Friday, February 14, 2026. The call will provide updated guidance, results, and commentary on the company's performance and strategic initiatives. The company has not yet released preliminary financial figures, but participants will expect updates on iron ore pricing, production volumes, and capital expenditures.

Orlando Berges, Chief Financial Officer of First Bancorp (FBC:NYSE), will retire effective April 30, 2026, following a 23-year tenure. Said Ortiz, currently Treasurer and Controller, has been named interim CFO and will serve in the role permanently upon completion of the transition. Berges' retirement follows a strategic leadership review, ensuring continuity in the company's financial operations. Ortiz brings extensive experience in risk management and capital strategy, with a track record of driving operational efficiency and compliance.